Accuray Signs Exclusive Distributor Agreement for Australia and New Zealand Markets with alphaXRT

SUNNYVALE, Calif., January 21, 2016 Accuray Incorporated (NASDAQ: ARAY) announced today that it has signed a distributor agreement with alphaXRT involving the CyberKnife® and TomoTherapy® System portfolios in Australia and New Zealand.  Under the terms of the agreement, alphaXRT will be the sole distributor for Accuray products in these territories.

“We are committed to growing our business and ensuring patients in the Australian and New Zealand markets have access to our systems,” said Roger Cao, President of Accuray APAC Region. “We are pleased to have the opportunity to work with alphaXRT and believe they will be an outstanding partner, based on their professional experience in the radiotherapy industry.”

Founded in 1991(as Alphatech International), alphaXRT is one of the leading regional distributors of equipment and software used in the treatment of cancer. With more than 20 years experience, alphaXRT has an in-depth knowledge of the radiosurgery and radiation therapy markets, and has built strong relationships within the oncology community. The Company’s sales team will use their industry expertise to identify and cultivate customers for Accuray products. The CyberKnife and TomoTherapy Systems have established the standard of care for patients requiring radiation therapy. These leading-edge technologies are used worldwide for highly precise treatment delivery to a wide range of cancerous and non-cancerous tumors throughout the body.

“The signing of this agreement is an exciting opportunity for alphaXRT to continue to provide innovative and valuable solutions for our customers,” said Richard Neale, Managing Director of alphaXRT. “We are looking forward to working with Accuray to expand the availability of the CyberKnife and TomoTherapy Systems in the region.”

About the CyberKnife and TomoTherapy Systems
The Accuray CyberKnife M6™ Series and TomoTherapy H™ Series treatment solutions cover the entire spectrum of radiation therapy needs. The CyberKnife M6 Series enables precise, high-quality, high-dose distributions to be confidently delivered to the patient with extreme accuracy over a minimum number of treatments, reducing side effects and preserving patients' quality of life. The CyberKnife System is the only robotic full-body radiosurgery system available today. The TomoTherapy H Series efficiently enables physicians to customize treatment plans for the entire range of radiation therapy patients and disease types. Its innovative design enables treatment plans to be delivered with integrated, daily CT image guidance, enhancing accuracy and delivering highly precise, intensity-modulated radiation for optimal sparing of healthy tissue and critical structures.

Further information on Accuray, the CyberKnife and TomoTherapy Systems is available at


About Accuray

Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments.

Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to company growth, market access and adoption, and Accuray’s leadership position in radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to the risks detailed under the heading “Risk Factors” in the company’s report on Form 10-K, filed on August 28, 2015, the company’s report on Form 10-Q, filed on November 5, 2015, and the company’s other filings with the SEC.

Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management’s good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.

About alphaXRT

alphaXRT is the leading independent distributor of software and equipment used in the treatment of cancer in Australia and New Zealand and represents a wide range of respected international suppliers.